A case of retroperitoneal dedifferentiated liposarcoma successfully treated by neoadjuvant chemotherapy and subsequent surgery.
Chemotherapy
Complete pathological response
Dedifferentiated
Retroperitoneal liposarcoma
Journal
Surgical case reports
ISSN: 2198-7793
Titre abrégé: Surg Case Rep
Pays: Germany
ID NLM: 101662125
Informations de publication
Date de publication:
24 May 2020
24 May 2020
Historique:
received:
13
02
2020
accepted:
07
05
2020
entrez:
26
5
2020
pubmed:
26
5
2020
medline:
26
5
2020
Statut:
epublish
Résumé
Retroperitoneal liposarcoma (RPLS) is the most commonly observed soft tissue sarcoma in the retroperitoneal space. Although the beneficial effect of chemotherapy for RPLS is controversial, there are some reports that have shown a considerable tumor-suppressive effect of chemotherapy in RPLS. We demonstrate a case of dedifferentiated RPLS, which was initially considered inoperable but was successfully treated by neoadjuvant chemotherapy and subsequent curative resection. A 59-year-old female was referred to our hospital with a chief complaint of right lower quadrant abdominal pain. Abdominal computed tomography revealed a large retroperitoneal tumor with a maximum diameter of 11 cm. The tumor involved retroperitoneal major vasculatures, such as the right common iliac vein and artery, as well as the right psoas muscle and femoral nerve. The right ureter was also involved and obstructed by the tumor. A biopsy was performed through the retroperitoneal route, and the tumor was diagnosed as a dedifferentiated liposarcoma with the Fédération Nationale des Centres de Lutte Contre le Cancer grade 3. Because the tumor was highly invasive and complete resection was not feasible, we decided to administer neoadjuvant chemotherapy with doxorubicin and ifosfamide (AI). After completing 6 courses of AI, the tumor size was considerably reduced, and we decided to perform surgery with curative intent. Before laparotomy, femoro-femoral arterial bypass was performed to prepare for the right common iliac artery resection. Thereafter, the patient underwent laparotomy and tumor resection combined with right nephrectomy, resection of the right common iliac artery and vein, and resection of the right psoas muscle and femoral nerve. The postoperative course was uneventful, although the patient needed a walking brace to support her gait. The pathological findings indicated a 99% disappearance of tumor cells. The patient was healthy without any complaints after 1 year of surgery, and a follow-up CT scan revealed no tumor recurrence. To the best of our knowledge, this is the first report that showed a nearly complete pathological response to AI in dedifferentiated RPLS, which was subsequently completely resected.
Sections du résumé
BACKGROUND
BACKGROUND
Retroperitoneal liposarcoma (RPLS) is the most commonly observed soft tissue sarcoma in the retroperitoneal space. Although the beneficial effect of chemotherapy for RPLS is controversial, there are some reports that have shown a considerable tumor-suppressive effect of chemotherapy in RPLS. We demonstrate a case of dedifferentiated RPLS, which was initially considered inoperable but was successfully treated by neoadjuvant chemotherapy and subsequent curative resection.
CASE PRESENTATION
METHODS
A 59-year-old female was referred to our hospital with a chief complaint of right lower quadrant abdominal pain. Abdominal computed tomography revealed a large retroperitoneal tumor with a maximum diameter of 11 cm. The tumor involved retroperitoneal major vasculatures, such as the right common iliac vein and artery, as well as the right psoas muscle and femoral nerve. The right ureter was also involved and obstructed by the tumor. A biopsy was performed through the retroperitoneal route, and the tumor was diagnosed as a dedifferentiated liposarcoma with the Fédération Nationale des Centres de Lutte Contre le Cancer grade 3. Because the tumor was highly invasive and complete resection was not feasible, we decided to administer neoadjuvant chemotherapy with doxorubicin and ifosfamide (AI). After completing 6 courses of AI, the tumor size was considerably reduced, and we decided to perform surgery with curative intent. Before laparotomy, femoro-femoral arterial bypass was performed to prepare for the right common iliac artery resection. Thereafter, the patient underwent laparotomy and tumor resection combined with right nephrectomy, resection of the right common iliac artery and vein, and resection of the right psoas muscle and femoral nerve. The postoperative course was uneventful, although the patient needed a walking brace to support her gait. The pathological findings indicated a 99% disappearance of tumor cells. The patient was healthy without any complaints after 1 year of surgery, and a follow-up CT scan revealed no tumor recurrence.
CONCLUSIONS
CONCLUSIONS
To the best of our knowledge, this is the first report that showed a nearly complete pathological response to AI in dedifferentiated RPLS, which was subsequently completely resected.
Identifiants
pubmed: 32448975
doi: 10.1186/s40792-020-00865-2
pii: 10.1186/s40792-020-00865-2
pmc: PMC7246274
doi:
Types de publication
Journal Article
Langues
eng
Pagination
105Références
Lancet Oncol. 2010 Jun;11(6):561-70
pubmed: 20434400
Ann Surg Oncol. 2018 Mar;25(3):754-767
pubmed: 28895107
J Surg Oncol. 2018 Jan;117(1):99-104
pubmed: 29193081
Eur J Cancer. 2017 Apr;75:33-40
pubmed: 28214655
Oncology. 2005;68(2-3):115-21
pubmed: 15886503
J Cancer Res Ther. 2015 Oct-Dec;11(4):974-6
pubmed: 26881560
Curr Probl Diagn Radiol. 2013 Sep-Oct;42(5):191-208
pubmed: 24070713
JAMA Oncol. 2016 Jul 1;2(7):937-40
pubmed: 27124835
Drug Des Devel Ther. 2015 Oct 27;9:5785-91
pubmed: 26604682
Cancer. 2019 Apr 15;125(8):1290-1300
pubmed: 30602058
Eur J Surg Oncol. 2018 May;44(5):571-579
pubmed: 29472043
Int J Clin Oncol. 2020 May;25(5):929-936
pubmed: 31950376
Ther Adv Med Oncol. 2017 Jun;9(6):415-429
pubmed: 28607580
Oncol Res Treat. 2019;42(7-8):396-404
pubmed: 31170709
Expert Opin Investig Drugs. 2019 Jun;28(6):505-511
pubmed: 31010343
Future Oncol. 2020 Jan;16(1s):25-32
pubmed: 31858818
BMC Cancer. 2018 Aug 22;18(1):842
pubmed: 30134855
Cancer. 2002 Sep 1;95(5):1120-6
pubmed: 12209699
J Surg Oncol. 2016 May;113(6):628-34
pubmed: 26990903